Temporary Pause In US Shipments From Sun Pharma's Plant In Mohali
Listen to This Article
United States Food and Drug Administration (USFDA) has asked Sun Pharmaceutical Industries to take certain corrective actions at the Mohali facility before releasing further final product batches into the US, the company said in the notification to the BSE on Sunday.
"The company is taking the required corrective steps, but there will be a temporary pause in the release of batches from Mohali until USFDA-mandated measures are implemented," Sun Pharma said.
US shipments from Mohali will resume once these measures are in place, it added.
Corrective actions include retaining an independent current good manufacturing practice (CGMP) expert to conduct batch certifications of drugs manufactured at the Mohali facility.
Sun Pharma got a consent decree correspondence/non-compliance letter from the US Food and Drug Administration for Mohali Facility.
The consent decree sets a strict timetable and requirements for the firm to ensure it obtains compliance with current good manufacturing practice (CGMP) requirements under the Federal Food, Drug, and Cosmetics Act (FD&C Act).
The facility at Mohali, Punjab was inspected from August 3 to August 12, 2022, and the USFDA classified the inspection as 'Official Action Indicated' (OAI).
“We now wish to inform you that the Company has received a letter titled 'Consent Decree correspondence/non-compliance letter’ from the US FDA. US FDA has directed the Company to take certain corrective actions at the Mohali facility before releasing further final product batches into the US,” Sun Pharma said.
The plant was under OAI status already, which is expected to impact approvals pending for products, but does not impact the current business from the facility. Last November, Sun Pharma had said that the OAI status is not likely to have any material adverse impact on the current business from the facility. It continued to manufacture and distribute existing products for the US market.
Monzo Looks For US Banking License
Monzo is preparing a renewed push to secure a US banking licence, four years after abandoning its first attempt when tal... Read more
Crypto Firms Push Into US Banking
America’s cryptocurrency companies are scrambling to secure a foothold in the country’s traditional banking system, ... Read more
Parallel Banking: Stablecoins Are Now Global
Parallel Banking: How Stablecoins Are Building a New Global Payments SystemStablecoins—digital currencies pegged to tr... Read more
JPMorgan Deploys AI Chatbot To Revolutionize Research And Productivity
JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more
Private Equity And Banks: The Complex Web Of Leverage
Private equity has emerged as a significant force in the global financial landscape, driving substantial growth and inve... Read more
Financial Watchdog Highlights Unresolved Vulnerabilities In Shadow Banking Sector
The world’s leading financial stability watchdog has issued a warning about the unresolved vulnerabilities within the ... Read more